Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Nihon Sanka Fujinka Gakkai Zasshi ; 44(3): 341-8, 1992 Mar.
Article in Japanese | MEDLINE | ID: mdl-1376759

ABSTRACT

From favorable results with 254-S, a new cisplatin analogue, single administration, we have conducted a clinical study to investigate the efficacy of combination of 254-S, ifosfamide and peplomycin, each of which has a different dose limiting factor. A total of 45 patients, including 22 patients with stage III and IV cervical cancer and 23 cases with recurrent cervical cancer, were treated with at least two courses of 254-S (100mg/m2, iv. Day 1), ifosfamide (1,500mg/body, iv. Day 1-5) and peplomycin (5mg/body, im. Day 1-6), and tumor response was evaluated clinically and by CT scanning. The response rate obtained in patients with advanced disease was 81.8% (PR = 17, CR = 1) and that in cases with recurrence was 60.9% (PR = 12, CR = 2). Myelosuppression was the dose limiting factor. In the 121 courses, grade 3 and 4 of leucopenia and thrombocytopenia were observed with an incidence of 44% and 32%, respectively and DIC occurred in 3 cases with poor PS though they recovered after reducing the 254-S dose to 80 mg/m2. The other toxicities were mild except for alopecia. Anaphylaxia was observed in a case at the second administration though the patient recovered in 15 minutes. There was no death. As to prognosis, a significant prolongation of survival period was observed in recurrent cases and 4 cases are alive (NED) after one and a half year. In the advanced cases, until now 3 cases of stage IV have died from the disease. We have concluded that this regimen is effective as a neoadjuvant chemotherapy for advanced cervical cancer and useful for the treatment of recurrent cervical cancer.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/drug therapy , Organoplatinum Compounds/therapeutic use , Uterine Cervical Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Antibiotics, Antineoplastic/administration & dosage , Antineoplastic Agents/administration & dosage , Bleomycin/administration & dosage , Combined Modality Therapy , Female , Humans , Ifosfamide/administration & dosage , Middle Aged , Neoplasm Recurrence, Local , Organoplatinum Compounds/administration & dosage , Peplomycin , Prognosis
2.
Nihon Sanka Fujinka Gakkai Zasshi ; 41(6): 647-52, 1989 Jun.
Article in Japanese | MEDLINE | ID: mdl-2671201

ABSTRACT

Temporary blockage of uterine and ovarian vessels with forceps led to an approximately two-fold increase in the transfer of LMOX and Carboplatin to uterine muscle, ovarian tissue and pelvic lymph-nodes after the release of forceps. This result suggests the importance of preserving these main vessels for the effective transfer of chemotherapeutic agents to target tissues. Ten cases in stage III or IV underwent cytoreductive surgery followed by three courses of CDDP, ADM, CPA chemotherapy and SLO (postop. group). A further 27 cases were given diagnostic laparotomy followed by the same chemotherapy and SLO (preop. group). Examination of both groups revealed the following: The efficacy rate of the CAP regimen was 77.8% in the preop. group and 50.0% in the postop. group; the surgical extirpation rate exceeding 90% at SLO was 76.1% and 50.0% in the preop. and postop. groups respectively. The survival period was longer in the preop. group, ie., two years in 69% versus 40% and three years 43% v 20% of the preop. and postop. groups, respectively. Preoperative (Neo-adjuvant) chemotherapy followed by aggressive surgery was concluded to be preferable to carrying out enforced reduction surgery first on such advanced cases where the mass of the residual disease cannot be left untouched is unavoidable.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Ovarian Neoplasms/drug therapy , Antineoplastic Agents/pharmacokinetics , Carboplatin , Cisplatin/administration & dosage , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Cystadenocarcinoma/drug therapy , Cystadenocarcinoma/metabolism , Cystadenocarcinoma/surgery , Doxorubicin/administration & dosage , Drug Administration Schedule , Female , Humans , Lymph Nodes/metabolism , Moxalactam/pharmacokinetics , Organoplatinum Compounds/pharmacokinetics , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/surgery , Ovary/blood supply , Ovary/metabolism , Remission Induction , Tissue Distribution , Uterus/blood supply , Uterus/metabolism
3.
Nihon Sanka Fujinka Gakkai Zasshi ; 37(1): 38-44, 1985 Jan.
Article in Japanese | MEDLINE | ID: mdl-3973437

ABSTRACT

74 cases of primary ovarian cancer treated here previously were classified into three groups, no residual (corresponding to Stage Ia, Ib), cell residual (Ic-IIc) and mass residual (III, IV), and prognoses were compared. The 5 year survival rates were 83.3%, 29.4% and 12.6% respectively. In Stage I and II cases, almost all of the tumor mass would be removed by operation. Therefore the target of postoperative treatment should be the residual cancer as cell units spread widely throughout the abdominal cavity. For this purpose, IPCP has been performed on 35 cases of Stage I and II since 1977. The 3 year survival rate for this series is as good as 88.6%, and the sites of recurrence were localized in the small pelvic cavity adjacent to the Douglas pouch in 5 out of 6 relapsed cases. This fact suggests that IPCP is capable of controlling the cancer cells in the upper abdominal cavity, but still insufficient to control them in the pelvic cavity where deeper invasion is suspected. In order to improve the local control ability, utilization of the uterus as the applicator for prophylactic intracavitary irradiation came to be considered. The spread of cancer to the uterus was found in 5 out of 38 cases in Stage I and II(13.2%), but silent invasion was found in only one case. These results suggests that the utilization of the uterus as the applicator for prophylactic intracavitary irradiation would be feasible if no macroscopical cancer extention to the uterus exists and the uterus is suitable for application. Several combinations with Tandem and Ovoid have been tested and an adequate method has been proposed.


Subject(s)
Brachytherapy , Ovarian Neoplasms/therapy , Uterine Neoplasms/prevention & control , Brachytherapy/methods , Combined Modality Therapy , Female , Humans , Neoplasm Recurrence, Local , Neoplasm Staging , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/radiotherapy , Ovarian Neoplasms/surgery , Postoperative Period , Radiotherapy Dosage , Uterine Neoplasms/radiotherapy
4.
Nihon Sanka Fujinka Gakkai Zasshi ; 34(7): 880-8, 1982 Jul.
Article in Japanese | MEDLINE | ID: mdl-7108307

ABSTRACT

With an attempt to diminish the post-transfusion hepatitis following radical hysterectomy, the study was made on 27 cases of cervical cancer undergone the operation. Fifty cases with blood transfusion immediately prior to the study was taken as control group. Under general anesthesia, 800 ml of venous blood was drawn from the peripheral vein under simultaneous infusion of 1,000 ml of Saviosol to maintain the circulating blood volume. The blood was returned after hemostatizing procedures. Of the study group, the blood loss, operation time, urinary output during the operation, and drainage amount were 960 g, 157 minutes, 350 ml and 160 ml respectively, while those of control group were 930 g, 164 minutes, 150 ml and 280 ml. The circulation status remained within normal limits, no bleeding tendency was appeared. Blood loss of the study group was estimated 960 g, however the actual blood loss calculated was on l6 719 g. There were no particular complication in the study group, while there was 12% of hepatitis among the control group. The advantages were concluded as 1) Patient was under normovolemic state when the operation started. 2) The blood transfused had normal O2 transport and hemostatic capacity. 3) The management of the patient was not so difficult and no special equipment and technique were needed.


Subject(s)
Hemodilution/methods , Hysterectomy , Preoperative Care/methods , Uterine Cervical Neoplasms/surgery , Female , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...